Tait D Shanafelt, MD
Hematology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Shanafelt’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C149730 · Current
Licensed to practise in California · since 2017 · expires 2028-09-30 · University of Colorado School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$20,128
Medicare paid this office $20,128 for 85 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 39 | $9,229 | $149 |
| Long return visit (40+ min) | 47 | $8,353 | $111 |
| New patient visit (60+ min) | 13 | $2,003 | $154 |
Who their Medicare patients are
85 Original Medicare patients in 2024. Average age 73 · Women 47% · Health risk score 1.54. At or below the middle of the specialty; the typical hematology clinician is at 2.35.
Conditions among them: High blood pressure 53% · Coronary heart disease 22% · Chronic kidney disease 19% · Diabetes 18% · Cancer 15% · Atrial fibrillation 13%.
The office billed $80,371, Medicare allowed $29,165 and paid $20,128; for 154 services of 4 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 85 | 154 | 73 | 1.54 | $80,371 | $20,128 |
| 2023 | 77 | 140 | 74 | 1.84 | $75,456 | $15,929 |
| 2022 | 87 | 146 | 74 | 1.67 | $105,380 | $17,658 |
| 2021 | 49 | 122 | 74 | 1.67 | $84,069 | $16,050 |
| 2020 | 24 | 63 | 75 | 2.68 | $28,586 | $5,337 |
| 2019 | 25 | 61 | 74 | 1.54 | $8,549 | $6,038 |
| 2017 | 45 | 50 | 68 | 2.90 | $9,287 | $5,650 |
| 2016 | 65 | 192 | 71 | 1.87 | $24,882 | $16,414 |
| 2015 | 66 | 179 | 72 | 1.54 | $25,634 | $15,459 |
| 2014 | 59 | 606 | 73 | 1.83 | $41,282 | $28,278 |
| 2013 | 68 | 187 | 73 | 1.89 | $24,732 | $15,914 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Long return visit (40+ min) | 69 | $14,362 | $111 |
| New patient visit (60+ min) | 11 | $1,566 | $142 |
2022: 2 services
| Long return visit (40+ min) | 70 | $13,887 | $117 |
| New patient visit (60+ min) | 25 | $3,701 | $148 |
2021: 3 services
| Long return visit (40+ min) | 30 | $9,229 | $128 |
| New patient visit (60+ min) | 27 | $4,685 | $174 |
| Return visit (30+ min) | 14 | $1,860 | $89 |
2020: 2 services
| Long return visit (40+ min) | 15 | $2,396 | $89 |
| Return visit (30+ min) | 16 | $1,849 | $71 |
2019: 2 services
| Long return visit (40+ min) | 17 | $3,656 | $91 |
| New patient visit (60+ min) | 12 | $1,770 | $148 |
2017: 2 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $2,792 | $147 |
| Long return visit (40+ min) | 18 | $1,822 | $87 |
2016: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $7,602 | $76 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,548 | $148 |
| Long return visit (40+ min) | 18 | $2,370 | $91 |
| Hospital discharge day management, 30 minutes or less | 21 | $1,173 | $53 |
2015: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $6,654 | $72 |
| Long return visit (40+ min) | 28 | $3,840 | $104 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,209 | $146 |
| Hospital discharge day management, 30 minutes or less | 12 | $615 | $51 |
2014: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $3,872 | $72 |
| Long return visit (40+ min) | 24 | $3,257 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,098 | $148 |
| Hospital discharge day management, 30 minutes or less | 11 | $585 | $53 |
2013: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $5,513 | $73 |
| Long return visit (40+ min) | 26 | $4,405 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $3,440 | $138 |
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Pharmacyclics LLC, an AbbVie Company · Ea9161: A Randomized Phase III Study of A Targeted Therapy Combination Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (Cll) · 2021 | Their institution | $94,291,122 |
| Pharmacyclics LLC, an AbbVie Company · Ea9161: A Randomized Phase III Study of A Targeted Therapy Combination Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (Cll) · 2022 | Their institution | $49,862,546 |
| ABBVIE INC. · Ea9161: A Randomized Phase III Study of A Targeted Therapy Combination Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (Cll) · 2024 | Their institution | $44,323,389 |
| Pharmacyclics LLC, an AbbVie Company · E1912: A Randomized Phase III Study of Pci-32765 Based-Therapy Versus Standard Fludarabine, Cyclophosphamide, and Rituximab (Fcr) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (Cll) · 2021 | Their institution | $38,783,067 |
| ABBVIE INC. · Ea9161: A Randomized Phase III Study of A Targeted Therapy Combination Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (Cll) · 2025 | Their institution | $36,701,267 |
| Pharmacyclics LLC, an AbbVie Company · E1912: A Randomized Phase III Study of Pci-32765 Based-Therapy Versus Standard Fludarabine- Cyclophosphamide- and Rituximab (Fcr) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (Cll) · 2022 | Their institution | $35,429,813 |
| ABBVIE INC. · E1912: A Randomized Phase III Study of Pci-32765 Based-Therapy Versus Standard Fludarabine, Cyclophosphamide, and Rituximab (Fcr) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (Cll) · 2024 | Their institution | $30,284,957 |
| Pharmacyclics LLC, an AbbVie Company · A Randomized Phase III Study of A Targeted Therapy Combination Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (Cll) · 2023 | Their institution | $22,294,293 |
| Pharmacyclics LLC, an AbbVie Company · A Randomized Phase III Study of Pci-32765 Based-Therapy Versus Standard Fludarabine, Cyclophosphamide, and Rituximab (Fcr) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (Cll) · 2023 | Their institution | $17,701,598 |
| Pharmacyclics LLC, An AbbVie Company · A Randomized Phase III Study of A Targeted Therapy Combination Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (Cll) · 2023 | Their institution | $17,673,686 |
| Pharmacyclics LLC, An AbbVie Company · A Randomized Phase III Study of Pci-32765 Based-Therapy Versus Standard Fludarabine, Cyclophosphamide, and Rituximab (Fcr) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (Cll) · 2023 | Their institution | $15,499,266 |
| ABBVIE INC. · E1912: A Randomized Phase III Study of Pci-32765 Based-Therapy Versus Standard Fludarabine, Cyclophosphamide, and Rituximab (Fcr) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (Cll) · 2025 | Their institution | $14,168,655 |
| AbbVie, Inc. · Venclexta · 2019 | Their institution | $11,291,985 |
| Pharmacyclics LLC, an AbbVie Company · A Randomized Phase III Study of A Targeted Therapy Combination Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (Cll) · 2022 | Their institution | $3,655,448 |
| Pharmacyclics LLC, An AbbVie Company · Ea9161: A Randomized Phase III Study of A Targeted Therapy Combination Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (Cll) · 2023 | Their institution | $2,678,885 |
| Genentech, Inc. · A Randomized Phase III Study of A Targeted Therapy Combination Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia Cll · 2020 | Their institution | $1,903,005 |
| Genentech, Inc. · A Randomized Phase III Study of A Targeted Therapy Combination Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia Cll · 2019 | Their institution | $1,243,297 |
| Pharmacyclics LLC, An AbbVie Company · Imbruvica · 2019 | Their institution | $1,227,743 |
| Genentech, Inc. · A Randomized Phase III Study of A Targeted Therapy Combination Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia Cll · 2021 | Their institution | $970,533 |
| Pharmacyclics LLC, An AbbVie Company · Imbruvica · 2020 | Their institution | $787,079 |
| Genentech, Inc. · A Randomized Phase III Study of A Targeted Therapy Combination Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia Cll · 2022 | Their institution | $380,601 |
| Pharmacyclics LLC, an AbbVie Company · A Randomized Phase III Study of Pci-32765 Based-Therapy Versus Standard Fludarabine, Cyclophosphamide, and Rituximab (Fcr) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (Cll) · 2022 | Their institution | $150,000 |
| Genentech, Inc. · Phase III Study of A Targeted Therapy Combination Versus Ibrutinib and Obinutuzumab in Untreated You · 2024 | Their institution | $116,338 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1295712677
- Licence
- CA C149730, MN 44085California C149730: Current · expires 2028-09-30
- Trained
- University of Colorado School of Medicine, Denver, 1998
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- MN 632660900
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X); Medical oncology (207RX0202X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2005-12-28
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.